Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Spero Therapeutics (Nasdaq: SPRO) will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, 2026, after market close.

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, 2026, after market close. Management will hold a conference call and live audio webcast at 5:00 p.m. EDT to discuss results, business, and pipeline updates.

Investors can join by dialing 1-877-407-0789 (domestic) or 1-201-689-8562 (international) using conference ID 13762082, or via a webcast link available on the Investors page of the Spero website. An archived webcast will remain accessible for 30 days.

Argus Aug 5 session 10 alerts

+2.44% close to close 0.3x rel. volume Open Argus

Details

News Market Reaction – SPRO

+3.3% Peak in 6 hr 6 min

$71.79M Market Cap

In the Aug 5 session, SPRO gained 2.44%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.3% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Prior earnings-date notices were followed by 4.55% and 0.41% 24-hour moves. That history frames this...

Analysis

Prior earnings-date notices were followed by 4.55% and 0.41% 24-hour moves. That history frames this scheduling update as a recurring calendar catalyst, while low short positioning limits squeeze-related volatility.

Key Figures

Reporting date: August 12, 2026 Quarter end: June 30, 2026

Reporting date

August 12, 2026

Q2 2026 financial results after market close

Quarter end

June 30, 2026

Second quarter 2026

Previous Earnings date Reports

2 past events · Latest: May 05

Same Type 2 events

1. May 05

   Q1 earnings-date notice

   24h Move

   +4.5%

   Scheduled Q1 2026 results after market close; no conference call planned.

2. Mar 18

   FY earnings-date notice

   24h Move

   +0.4%

   Scheduled Q4 and full-year 2025 results after market close; no conference call planned.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that announced that it will report its financial results for the second quarter ended June 30, 2026 on Wednesday, August 12, 2026, after market close. Management will host a conference call and live audio webcast beginning at 5:00 pm EDT to discuss the results and provide a business and pipeline update.

To access the call, please dial 1-877-407-0789 (domestic) or 1-201-689-8562 (international) and refer to conference ID 13762082, or click on this link to request a return call. The webcast for the event can be accessed live on this link, or on the Investors page of the Spero Corporate website at https://www.sperotx.com/. The archived webcast will be available for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation for patients with serious diseases and major treatment gaps. The Company’s lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with a broad potential for additional immune-related conditions. For more information, visit www.sperotx.com.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com

Media Inquiries:
media@sperotherapeutics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Spero Therapeutics (SPRO) report its Q2 2026 financial results?

Spero Therapeutics will report its Q2 2026 financial results on Wednesday, August 12, 2026, after market close. According to Spero Therapeutics, management will also host a conference call and webcast at 5:00 p.m. EDT to discuss results, business developments, and pipeline updates.

How can investors join the Spero Therapeutics (SPRO) Q2 2026 earnings conference call?

Investors can join the Spero Therapeutics Q2 2026 call by dialing 1-877-407-0789 domestically or 1-201-689-8562 internationally, using conference ID 13762082. According to Spero Therapeutics, participants may also click the provided link to request a return call for easier access.

Will Spero Therapeutics (SPRO) provide a webcast for the Q2 2026 earnings and business update?

Yes, Spero Therapeutics will provide a live audio webcast for its Q2 2026 earnings and business update. According to Spero Therapeutics, the webcast can be accessed via a dedicated link or through the Investors page on the company’s corporate website at https://www.sperotx.com/.

How long will the Spero Therapeutics (SPRO) Q2 2026 earnings webcast archive be available?

The archived webcast of Spero Therapeutics’ Q2 2026 earnings call will be available for 30 days following the event. According to Spero Therapeutics, investors can access this replay through the same webcast link or via the Investors section of the company website.

What will Spero Therapeutics (SPRO) discuss during the Q2 2026 earnings call on August 12, 2026?

During the Q2 2026 earnings call, Spero Therapeutics management will discuss quarterly financial results, a business update, and pipeline progress. According to Spero Therapeutics, the event combines financial reporting with a broader overview of its clinical-stage programs in immunology and inflammation.